|
mandates sponsors to report Adverse Drug Reactions (ADRs) that are determined to be both serious and unexpected to the OCT and the Office of Regulatory Affairs, BGTD, as applicable. ADR reports that are expected or unexpected, but not serious, should not be reported to the OCT in Health Canada nor the BGTD, but rather monitored and tracked by the sponsor. Sponsors are to report to Health Canada "expected, serious" ADRs, where an increase in the rate of occurrence or severity, was judged to be clinically important.
|